The synthetic glucocorticoid dexamethasone is administered to many patients receiving a general anaesthetic to reduce the risk of postoperative nausea and vomiting. Dexamethasone is known to suppress the hypothalamic-pituitary-adrenal axis; however, the duration of this suppression following the standard anti-emetic intravenous dose of 4 to 8 mg used with anaesthesia is unknown.
Dexamethasone significantly reduces postoperative nausea and vomiting 1 and may reduce postoperative pain 2 . Patients undergoing a major surgical procedure, or those with a history of significant postoperative nausea and vomiting, often receive a single 4 to 8 mg intravenous dose of dexamethasone intraoperatively. In general, dexamethasone appears to be safe and effective in adults 1-3 although it may be associated with an increase in blood glucose levels, particularly in obese patients with impaired glucose tolerance 4 .
Dexamethasone is a synthetic glucocorticoid with a duration of action of 36 to 72 hours and a plasma half-life of approximately six hours 5 . As dexamethasone is 25 times more potent than cortisol 6 and does not cross-react with the cortisol assay, low dose dexamethasone is used in suppression tests to assess the possibility of Cushing's syndrome 7 .
A single 8 mg dose of dexamethasone would be expected to result in acute adrenal suppression in individuals without Cushing's syndrome. Despite the widespread use of dexamethasone to prevent postoperative nausea and vomiting, there has been only one previous study reporting the degree of cortisol suppression in this setting. Cowie et al demonstrated that cortisol levels were suppressed to <5% of baseline at 24 hours after a single 8 mg dexamethasone dose in patients undergoing elective laparoscopic cholecystectomy 8 . However, as cortisol levels were not studied for more than 24 hours, the duration of cortisol suppression is not known.
In addition to the hypothalamic-pituitary-adrenal axis, dexamethasone is known to suppress other pituitary hormones including the gonadal and thyroid axes 9, 10 . The extent and duration of suppression following a single 8 mg dose of dexamethasone on these axes is also unknown. The aim of this study was to assess the duration of hypothalamicpituitary-adrenal axis suppression and effect on blood glucose, gonadal and thyroid function after a standard 8 mg dexamethasone dose as compared with saline control in healthy individuals. The primary endpoint was to determine when the 0800hour cortisol level returned to baseline after administration of 8 mg intravenous dexamethasone. Secondary endpoints were the changes in Synacthen ® (Novartis Pharmaceuticals New Zealand Ltd, Auckland, New Zealand) stimulated plasma cortisol, thyroid and gonadal hormones and plasma glucose levels in the dexamethasone group as compared with placebo controls.
MATERIALS AND METHoDS
Ethics approval for this study was obtained from the Northern Y Regional Ethics Committee (Approval No. NTY/11/05/050) and the study was prospectively registered with the Australian New Zealand Clinical Trials Registry (Approval No. ACTRN12611001067965).
This was a randomised controlled double-blind crossover study conducted in New Zealand. Eligible participants were healthy male volunteers aged 18 to 45 years. Excluded from the study were individuals receiving exogenous steroids or medications which may affect dexamethasone metabolism and those who had an acute illness, diabetes mellitus or were nightshift workers. All individuals underwent baseline adrenal and pituitary function testing, including a Synacthen test (0.25 mg tetracosactide hexaacetate intravenously with plasma cortisol measures at 0, 30 and 60 minutes) performed at 0800 hours to ensure normal baseline adrenal and pituitary function. Immediately following Synacthen testing, individuals received either dexamethasone 8 mg intravenously or 2 ml saline control.
given the only previous study of this kind reported that a sample size of seven in each group was sufficient to detect a significant change in cortisol at 5 and 24 hours with a power of 0.8 (with a fall to less than 50% of baseline considered significant suppression) 8 , this study was conducted using ten healthy volunteers in a crossover design.
The order of treatment was randomised (by computerised sequence generation with numbers enclosed in opaque envelopes) and the crossover treatment was given after a minimum four-week washout period. Both participants and investigators were blinded to the treatment received, until completion of the trial. The dexamethasone or saline control was drawn up by a non-blinded specialist endocrine nurse who was not part of the study. Following dexamethasone or placebo administration, blood samples were collected at 4 and 8 hours after 8 mg intravenous dexamethasone for adrenocorticotropin (ACTH), cortisol and glucose levels. For the following four days 0800-hour blood samples were collected for ACTH, cortisol, dehydroepiandrosterone sulphate (DHEAS), thyroxine (FT 4 ), free triiodothyronine (FT 3 ), thyroid stimulating hormone (TSH), luteinising hormone, follicle stimulating hormone, testosterone, sex hormone-binding globulin and glucose. on the first day post dexamethasone or placebo a repeat Synacthen test was performed at 0800 hours.
ACTH and DHEAS were measured using an Immulite immunoassay (Siemens Healthcare Diagnostics Inc, Deerfield, IL, USA). Cortisol, FT 4 , FT 3 , TSH, luteinising hormone, follicle stimulating hormone, sex hormone-binding globulin and testosterone were measured using a Roche Modular Analytics E170 immunoassay (Roche Diagnostics, Mannheim, germany). glucose was measured using the Cobas Roche (Roche Diagnostics, Mannheim, germany).
Statistical analysis compared between-group differences and changes from baseline to subsequent levels using a Wilcoxon Matched Pairs test and Mann-Whitney U test as appropriate, since the group sizes were small and several parameters were not normally distributed within the sample. All analyses were conducted using Statistica version 11 (StatSoft Inc, Tulsa, oK, USA). A P value of <0.05 was considered significant.
RESULTS
All volunteers had normal baseline plasma glucose levels, pituitary and adrenal function including Synacthen testing.
Adrenal axis
At four and eight hours after 8 mg intravenous dexamethasone, cortisol levels were not significantly different from placebo (P=0.80 and 0.97, respectively). By 0800 hours on day 1 following dexamethasone, the cortisol level had dropped from a median level of 470 to 19 nmol/l (4.04% of baseline, reference range [RR] 200 to 700 nmol/l; P=0.000011) and returned to normal during the subsequent day ( Figure 1 ). ACTH levels were significantly lower in the dexamethasone group on day 1 (P=0.000043) and returned to baseline by day 2 (47 hours) post dexamethasone administration.
Synacthen-stimulated cortisol levels were not significantly different between the dexamethasone and placebo groups at baseline prior to treatment (P=0.623). on day 1 following dexamethasone administration, the median 0, 30 and 60-minute cortisol levels were significantly lower than in the placebo group (P=0.00001 at 0800 hours and 30 minutes, and P=0.000725 at 60 minutes) ( Figure 2 ).
Median DHEAS levels were not significantly different in the dexamethasone group as compared with placebo at any time point.
Thyroid axis
Median TSH levels had dropped by 8 hours after dexamethasone administration as compared with placebo (0.59 vs 1.10 mIU/l [RR 0.3 to 4.0 mIU/l]; P=0.0015) and remained significantly lower until day 2 (47 hours) post dexamethasone when levels were significantly higher (P=0.023) (Figure 3 ). TSH levels also dropped significantly in the placebo group from baseline to 8 hours (median 2.0 to 1.1 mIU/l) (P=0.008).
on day 1 post dexamethasone, FT 3 levels dropped below the lower limit of the reference range (RR 3.8 to 6.2 pmol/l) in three subjects and on day 3, FT 3 levels became elevated in four participants, while on day 4, three participants had elevated FT 3 levels. Median FT 3 levels were lower in the dexamethasone group (3.9 vs 4.9 pmol/l) at day 1 post dexamethasone (P=0.0039). FT 4 levels became elevated in two subjects although median FT 4 levels were not significantly different in the dexamethasone group as compared with the placebo group at any of the time points.
Pituitary gonadal axis
There were no significant differences in the median luteinising hormone, follicle stimulating hormone or sex hormone-binding globulin levels between the groups at any of the time points. Median testosterone levels were only lower in the dexamethasone group as compared with placebo group (12.2 vs 16.6 nmol/l [RR 9 to 30 nmol/l]) at day 1 post dexamethasone (P=0.0185) and had returned to baseline by the following day.
Plasma glucose
Plasma glucose levels were higher in the dexamethasone group at 4 and 8 hours (P<0.0001) post dexamethasone as compared with placebo, but were no longer elevated by 0800 hours on day 1 (Figure 4 ).
DISCUSSIoN
This study confirms the findings of Cowie et al that a single dose of 8 mg dexamethasone causes a significant reduction in cortisol levels by 24-hours post dose 8 . By 47 hours post dexamethasone the cortisol level was not significantly different from the placebo group. However, there was inter-individual variability with two individuals having subnormal (<200 nM) cortisol levels 48 hours post dexamethasone. This is relevant as patients may have postoperative plasma cortisol measured (e.g. due to development of postoperative hypotension which has not been explained by more common causes such as hypovolaemia) and these individuals may be misdiagnosed as having adrenal insufficiency. In contrast to a previous report in which cortisol levels dropped by 50% within 2 hours of an 8 mg dose 11 , we did not see an early reduction in cortisol levels as compared with placebo. This may be due to the pre-dexamethasone Synacthen test that may have masked an early reduction of cortisol levels in the dexamethasone group. However, in both groups cortisol levels dropped to 25% of baseline by 8 hours post dexamethasone. This is likely to be due to the normal cortisol changes with the circadian rhythm 12 .
A blunting of the peak cortisol response to Synacthen testing was demonstrated in the dexamethasone group at 24 hours post dose. This suggests that the adrenal glands are unable to mount the same peak response as prior to dexamethasone. one possible explanation is that this may be due to direct adrenal suppression by dexamethasone as the glucocorticoid receptor is widely expressed, including by the adrenal cortex 13 . Early studies investigating direct adrenal suppression by glucocorticoids produced conflicting results although some animal studies appeared to demonstrate direct suppression of the adrenal cortex 14, 15 . Theoretically, direct acute adrenal suppression by dexamethasone may occur in addition to the pituitary and hypothalamus, but this needs further investigation.
Alterations in the thyroid axis were demonstrated in response to dexamethasone, with TSH levels decreasing and then rebounding, which was mirrored to a lesser degree by the free thyroid hormone levels. TSH levels also decreased in the placebo group from baseline to 8 hours post dexamethasone. This may be due to the known diurnal rhythmicity of TSH 16 and may also be contributed to by the rise in cortisol from the Synacthen test performed prior to placebo administration. Changes in the thyroid axis occurring in critically ill patients have been well described 17 and here we demonstrate that a similar pattern occurs after a single dose of dexamethasone. This effect may be magnified in the postoperative patient, making interpretation of thyroid hormone levels (in particular TSH levels) difficult to interpret in the postoperative setting.
Similarly, changes in the gonadal axis occurred after dexamethasone, although median testosterone levels remained within the reference range. Inter-individual variability was again demonstrated with one subject dropping well below the reference range and only returning to normal by day 3 post dexamethasone. As for thyroid hormone assessment, measurement of testosterone levels have to be interpreted with care in acutely unwell patients, or, as demonstrated here, even in well patients receiving a single dose of dexamethasone.
Cowie et al demonstrated a significantly increased plasma glucose level at 24 hours following dexamethasone in postoperative patients 8 . We also demonstrated a rise in plasma glucose levels even in young healthy volunteers at 4 and 8 hours post dexamethasone with levels not returning to baseline until the following day. This increase in plasma glucose may be exaggerated in patients undergoing surgery due to other hormonal changes (e.g. increased catecholamine levels) and particularly if there is underlying insulin resistance or overt diabetes. This may be clinically important as elevated glucose levels may impair healing and increase infection rates. In addition, glucocorticoids have a myriad of effects on the immune system 18 , which theoretically may place patients at an increased risk of infection. greater cumulative duration of glucocorticoids in children undergoing complex cardiac surgery is associated with infection 19 . However, to date, most studies assessing infection rates in patients receiving a single perioperative dose of dexamethasone have not demonstrated an increased risk of infection [20] [21] [22] . one of the difficulties in interpreting the interindividual differences in the hormonal responses to dexamethasone may be due to differences in clearance of dexamethasone between individuals. Unfortunately we were unable to clarify this clearance issue as we were not able to measure the serum dexamethasone level or the metabolic clearance of this drug between individuals. Further studies are needed to address this issue. A further limitation of this study is that these patients did not have a general anaesthetic nor the stress of surgery, so future studies should be conducted in the perioperative setting. An 8 mg dose of dexamethasone was selected for this study as it was the dose commonly used intraoperatively in our institution and as used by Cowie et al 8 ; however, a recent meta-analysis suggests that a 4 to 5 mg of dexamethasone is probably as efficacious as an 8 to 10 mg dose 23 . This lower dose of dexamethasone is still supraphysiological and further assessment of this dose on blood glucose levels is important.
CoNCLUSIoNS
A dose of 8 mg of dexamethasone results in significant suppression of the hypothalamic-pituitaryadrenal axis. This suppression is maximal at 24 hours post dose and may lead to a misdiagnosis of adrenal insufficiency based on low cortisol levels if measured over this time. A blunted Synacthenstimulated cortisol peak suggests that partial direct adrenal suppression by dexamethasone may occur. A significant elevation in plasma glucose levels occurs after high dose dexamethasone administration even in healthy volunteers and this may be more pronounced in perioperative diabetic patients.
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